What We Can Learn From Bill Ackman Walking Away From Valeant Pharmaceuticals Intl Inc.

Investors can learn a lot from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Recently, it was announced that hedge fund manager Bill Ackman sold his firm’s entire stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). By selling his final position, he has done what many investors hate to do: he locked in losses.

Almost every investor has at least one position in their portfolio that is held at a loss. When an investor enters a position and sees the investment decline in value by say 20%, it is important to understand what needs to happen for the investor to be able to recoup their original investment. Using very simple math, an investment of $100 which declines by 20% to $80 needs to return to $100 for the investor to be even.

Assuming we hit the reset button here, a new investor may purchase the shares at $80 and get a $20 return divided by the initial outlay of $80, which translates to a return of 25%, not 20%!

For investors holding positions that are slightly at a loss, the amount a stock must come back to make up the loss is nothing more than a rounding error. Once it gets beyond 20-25%, however, the numbers are a little more serious.

With a loss of 10% as an example, the return must be 10/90 = 11.1%, meaning a difference of 1.1% — a very minor number.

Valeant shares have declined close to 90% since Ackman made the initial investment, translating to a return of (90/10) = 900% for his firm to get back to even. Although we’ve seen the hedge fund manager do fantastic things in the past, any investor hoping for a return of 900% is dreaming.

The amount of interest expenses as a percentage of revenue is simply too high for this company to survive over the long term, translating to a desperate need to either drastically increase revenue or repay debt.

As it is difficult to increase revenues, the second option is to pay off debt. Debt is close to $30 billion, and that can only mean selling assets or doing a secondary share issue. The challenge with this possibility is that Valeant has $30 billion in debt but a market capitalization of only approximately $5 billion. If the float were to double, the debt would only be reduced by approximately 16.5% or so.

And it seems the company is in for the fight of a lifetime after losing one of the heavyweight members of the board of directors.

Although the company has many excellent products to offer consumers, the reality is, the debt burden is simply too much to carry at this point. Bankruptcy may take months from here, but it’s inevitable — the fat lady will sing!

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

ETFs can contain investments such as stocks
Dividend Stocks

Want to Build Your Own Pension? Here’s How Canadian Dividend ETFs Can Help

Canadian dividend ETFs can provide tax-efficient monthly income with built-in diversification and low fees.

Read more »

Concept of multiple streams of income
Dividend Stocks

BCE or Telus? Here’s the Better Dividend Stock Right Now

BCE (TSX:BCE) and Telus (TSX:T) looks like stellar dividend value plays, but only one can be the better bet.

Read more »

crisis concept, falling stairs
Dividend Stocks

This Monthly Dividend Stock Is Still Cheap. Falling Rates Could Change That

RioCan’s properties are nearly full and rents are rising, yet the units still trade at a discount and yield over…

Read more »

Investor wonders if it's safe to buy stocks now
Dividend Stocks

What’s Actually Going on With Telus’s Dividend?

Telus (TSX:T) shares got crushed after the dividend was cut, but it might be too late to give up on…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, August 21

After posting its fourth decline in five sessions, the TSX could get some support from rallying metals prices today, although…

Read more »

dividend growth for passive income
Dividend Stocks

Buy the Dip: This Dividend-Growth Giant Just Dropped 14%

This top TSX dividend-growth stock now looks interesting.

Read more »

Canadian investor contemplating U.S. stocks with multiple doors to choose from.
Dividend Stocks

Enbridge vs. Telus: Which Is the Better Dividend Stock to Own Through 2030?

Enbridge and Telus have been popular because of their attractive dividend payouts. But their dividend stories now look quite different.

Read more »

holding coins in hand for the future
Energy Stocks

2 Dividend Stocks to Hold in a TFSA for 20 Years

Decades of dividend growth have driven these stocks higher over the long run.

Read more »